Sponsor:
Baylor College of Medicine
Code:
NCT04664179
Conditions
EBV-Related Hodgkin Lymphoma
EBV-Related Lymphoproliferative Disorder
EBV Related Non-Hodgkin's Lymphoma
Eligibility Criteria
Sex: All
Age: 0+
Healthy Volunteers: Not accepted
Interventions
Dose Level 1A: 2 x 10^7 cells/m2
Dose Level 2A: 6 x 10^7 cells/m2
Dose Level 2B: 6 x 10^7 cells/m2
Dose Level 3B: 2 x 10^8 cells/m2
Dose Level 3A: 2 x 10^8 cells/m2
Brief summary:
Conditions
EBV-Related Hodgkin Lymphoma
EBV-Related Lymphoproliferative Disorder
EBV Related Non-Hodgkin's Lymphoma
Study ID
NCT04664179
Start date
Oct 31, 2022
Status verified date
Jun, 2026
Completion date
Nov, 2042
Anticipated
Primary completion date
Nov, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 0+
Healthy Volunteers: Not accepted
Enrollment
52 participants
Anticipated
Allocation
Non randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: Arm A: Treatment without lymphodepletion chemotherapy
experimental: Arm B: Treatment with lymphodepletion chemotherapy
Interventions
Dose Level 1A: 2 x 10^7 cells/m2
Dose Level 2A: 6 x 10^7 cells/m2
Dose Level 2B: 6 x 10^7 cells/m2
Dose Level 3B: 2 x 10^8 cells/m2
Dose Level 3A: 2 x 10^8 cells/m2
Dose Level 1B: 2 x 10^7 cells/m2
Primary outcome measure
Central contacts
Locations
Houston Methodist Hospital
Recruiting
Houston, Texas, United States, 77030
Contacts
Sponsor
Baylor College of Medicine
Last update posted
Jun 25, 2026
Last verified
Jun, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Baylor College of Medicine on 2026-06-25.